Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
63 hedge funds and large institutions have $215M invested in Eiger BioPharmaceuticals, Inc. in 2019 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 18 increasing their positions, 18 reducing their positions, and 15 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
36% more capital invested
Capital invested by funds: $158M → $215M (+$57.4M)
0% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 18
7% less funds holding
Funds holding: 68 → 63 (-5)
33% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.51M |
| 2 |
EP
Eversept Partners
New York
|
+$933K |
| 3 |
LCM
Laurion Capital Management
New York
|
+$852K |
| 4 |
BC
Broadfin Capital
New York
|
+$669K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$665K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IVM
InterWest Venture Management
San Francisco,
California
|
-$6.34M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.21M |
| 3 |
AG
Algert Global
San Francisco,
California
|
-$541K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$492K |
| 5 |
FI
Fosun International
Hong Kong,
China
|
-$490K |
EIGR Hedge Fund Activity: Q1 2019 in Review
63 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q1 2019, worth a combined $215M — up 36% from $158M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of EIGR and 10 opened new positions — a net loss of 5 holders — while 18 trimmed existing stakes and 18 added.
The largest buyer was Millennium Management, adding an estimated $2.51M. The largest seller was InterWest Venture Management, cutting an estimated $6.34M.
- 63 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q1 2019, down from 68 in Q4 2018.
- Funds reported $215M of Eiger BioPharmaceuticals, Inc. stock for Q1 2019, up 36% quarter-over-quarter.
- 10 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q1 2019 and 15 closed out, a net change of -5 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q1 2019 was Millennium Management, an estimated $2.51M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q1 2019 was InterWest Venture Management, an estimated $6.34M sold.
Based on aggregated 13F filings for Q1 2019.